Eventide Asset Management’s PTC Therapeutics PTCT Stock Holding History

Eventide Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-34,047	Closed	-$1.65M	–	151
2023 Q1	$1.65M	Buy	+34,047	New	+$1.56M	0.03%	137
2019 Q1	–	Sell	-113,000	Closed	-$3.88M	–	134
2018 Q4	$3.88M	Sell	113,000 -131,000	-54%	-$4.71M	0.17%	91
2018 Q3	$11.5M	Buy	244,000 +175,800	+258%	+$7.27M	0.42%	70
2018 Q2	$2.3M	Hold	68,200	–	–	0.1%	109
2018 Q1	$1.84M	Hold	68,200	–	–	0.09%	115
2017 Q4	$1.14M	Hold	68,200	–	–	0.06%	126
2017 Q3	$1.36M	Buy	+68,200	New	+$1.34M	0.08%	117

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Eventide Asset Management's PTCT Position: Q2 2023 in Review

Eventide Asset Management sold out of PTC Therapeutics (PTCT) in Q2 2023, closing a stake of 34,047 shares — an estimated $1.65M sold.

Eventide Asset Management first reported a position in PTCT in Q3 2017 and held it in 7 quarters. The position peaked at $11.5M in Q3 2018. 204 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

Eventide Asset Management reported no remaining PTC Therapeutics position as of Q2 2023 after selling out during the quarter.
Eventide Asset Management sold 34,047 PTC Therapeutics shares in Q2 2023, an estimated $1.65M.
Eventide Asset Management first reported a position in PTC Therapeutics in Q3 2017 and held it in 7 quarters.
Eventide Asset Management's PTC Therapeutics position peaked at $11.5M in Q3 2018.
204 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on Eventide Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.